- Home
- HTD vs XERS Comparison
HTD vs XERS Comparison
Compare HTD & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTD | XERS |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.3M | 1.0B |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HTD | XERS |
|---|---|---|
| Price | $25.65 | $6.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 62.3K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | N/A | $22.86 |
| P/E Ratio | ★ N/A | $693.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $22.40 | $4.36 |
| 52 Week High | $26.21 | $10.08 |
Technical Indicators
Market Signals| Indicator | HTD | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 59.13 | 66.55 |
| Support Level | $24.29 | $6.86 |
| Resistance Level | $25.71 | $7.14 |
| Average True Range (ATR) | 0.37 | 0.25 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 78.03 | 87.01 |
Price Performance
Historical ComparisonAbout HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.